Overexpression of FRα in the blood-accessible basal and lateral membranes of epithelial carcinomas, and suggested contributions to tumor cell growth and proliferation, together point to targeting FRα as an attractive and potentially non-toxic treatment approach. Here, FOLR1 is linked to carcinoma.